Dolutegravir moves nearer first filings as Shionogi bolsters R&D ahead of Crestor cliff
This article was originally published in Scrip
Executive Summary
The first approval filings for the lead HIV integrase inhibitor dolutegravir (S/GSK-349572) being developed by the Shionogi-ViiV Healthcare joint venture are planned during the fiscal year ending 31 March 2013, the Japanese partner has said.